ClinicalTrials.gg
RecruitingNCT05233605PET-DEXDOCOVIDUpdated Dec 24, 2024

Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation

An observational study in Severe COVID-19, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2024-12-24.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Other
Enrollment
72
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris — 9 open to participants now, 11 under way, 2 of them phase 3. COVID-19 · Assistance Publique - Hôpitaux de Paris.

Planned enrollment
45th of 56
72 · median 489
Started
2022
with 7 others
Observational
56 of 115
5 open now
Primary completion
2026-02
later than 8 of 10 live
Registered
99th of 115
by date

Among the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, this one is the 45th largest by planned enrollment of the 56 observational ones that give a count, is one of 8 that started in 2022, is one of 56 observational ones, reaches primary completion later than 8 of the 10 other live ones, and was the 99th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

9 of the 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in COVID-19 by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

ICU Patients admitted after ARDS due to COVID infection should be weaned from invasive mechanical ventilation as quickly as possible.

60% of ARDS patient after COVID infection admitted in ICU developp a delirium during mechanical ventilation weaning, serious event that can lead to death or acute and late complications since 30% of patients who had a delirium in ICU develop cognitive sequelae. Based on epidemiological arguments and mouse models, severe neuroinflammation is considered to be one of the physiopathological mechanisms causing delirium during ventilatory weaning.

In addition to its sedative properties, dexmedetomidine exhibits neuroprotective effects. In experimental models, dexmedetomidine reduces brain inflammation acting directly on the microglial phenotype. The role of this chronic neuroinflammatory condition on cognitive abilities and reserve begins to emerge in the literature no matter the initial stress is (surgery, head trauma, or Alzheimer's type dementia) and is therefore able to influence quality of life. The evaluation of this neuroinflammation by non-invasive tools appears essential in the management and follow-up of post-COVID cerebrolesed patients, as well as the potentially neuroprotective evaluation of dexmedetomidine.

Read the detailed description

COVID-19 is responsible of a pandemic since December 31 2019, which began in China and spread rapidly. Confirmed Covid positive patients worlwide is estimated at 179 M in June 2021. The infection started in France at the beginning of 2020 and causes severe pneumonia with 130,519 confirmed cases, including 2,712 (2.1%) hospitalizations in intensive care units. COVID-19 emerges as a poorly understood systemic disease that affects several organs, especially the lungs. The first reason for worsening and hospitalization in intensive care is acute respiratory distress syndrome (ARDS) that requires heavy and long care management with orotracheal intubation and mechanical ventilation, as well as prolonged sedation and curarization. Patients who survived this critical phase should then be weaned from this invasive monitoring as quickly as possible to limit risk of morbidity and mortality. It therefore appears essential to do everything possible to reduce the duration of mechanical ventilation and the period of ventilatory weaning, a real daily challenge in intensive care, for both medical and socio-economic sides.

Beside COVID-19 infection, the ventilatory weaning phase is a long and difficult period that can last more than 40 to 60% of the time spent under mechanical ventilation and can be more complicated as the duration of sedation is prolonged. This phase is correlated with the duration of mechanical ventilation, as well as with respiratory, cardiac and neuromuscular diseases. Considering all the risk factors for prolonged ventilatory weaning, one of these is the intensive care delirium.

Delirium in intensive care is a serious event, possibly leading to mortality or acute and late complications (self-extubation, catheter removal, ...) since 30% of delirium patients develop cognitive sequelae. The incidence of this post-ARDS delirium is approximately 20% according to the studies and is found predominantly in patients with severe sepsis. The academic tool to access delirium in intensive care is the CAM-ICU (Confusion Assessment Mehod - ICU) scale; the RASS score (Richmond Agitation-Sedation Scale) is also usable to access patients with a hyperactive form (RASS score greater than 2).

Several drug strategies based on the use of sedating agents such as dexmedetomidine or certain neuroleptics such as loxapine or haloperidol have been developed to reduce this incidence. Dexmedetomidine is a selective adrenergic receptor agonist and has hypnotic and analgesic properties.

At the same time, dexmedetomidine exhibits neuroprotective effects. In experimental models such as intraperitoneal injection of lipopolysaccharide or LPS, marrow lesions or ischemia-reperfusion models, dexmedetomidine reduces cerebral inflammation with a direct action on the microglial phenotype. The impacted signaling pathway is still unclear, however several studies show an action of dexmedetomidine on the AMPK pathway. The use of dexmedetomidine to prevent and treat delirium is not uniform within intensive care units in France and is not administered systematically.

Unexpectedly, two thirds of patients hospitalized in intensive care for ARDS after COVID-19 infection develop a severe delirium. This unique incidence is double the incidences found in other populations in ICU (sepsis, meningitis,...).

Neuroinflammation reaction induced by an intra or extra-cranial phenomenon is a very studied process.

The latter is totally correlated with the strength of the stimulus and can be the cause of a disturbance or a complete runaway of the immune system described in the literature as an inflammatory storm. This neuroinflammation induced during the IC hospitalization is now known to persist, until several years after outbreak.

The role of this chronic neuroinflammatory persistent response on cognitive capacities and reserve begins to emerge in the literature regardless of the initial stress (surgery, head trauma, or Alzheimer-type dementia) and is therefore capable of influencing the quality of life of patients. The evaluation of this neuroinflammation using non-invasive tools appears to be essential in the management of cerebrolesed patients.

Among existing tools, positron emission tomography (PET) imaging using radiotracers specific for monocytic/microglial activation is now recognized as a relevant tool because of its sensitive and specific characteristics to assess brain inflammation. Several radiotracers have been tested, in particular [11C] -PK11195, but it is [18F] -DPA-714 or DPA that is retained in the literature because it has many pharmacokinetic advantages. He has indeed shown his interest in a few animal and human models in various pathologies. It should be noted that the DPA receptor exhibits a polymorphism that may explain certain differences in binding observed in humans. This tool, by means of a quantitative and possibly regional measurement of the signal measurement, is particularly innovative and seems to correlate with cognitive disorders, particularly in the context of Alzheimer's disease. Currently, the technology combining MRI and PET imaging with DPA appears to be the most successful for evaluating neuroinflammation, allowing regional measurement with better resolution. Recent studies have also been able to show that the increase in DPA by PET-MRI was associated with a pejorative cognitive evolution.

The role of peripheral inflammation on the neuro-inflammatory profile is now well described with both mediation via cytokines / chemokines produced by systemic immunity but also by infiltration and cellular exchanges of the monocyte / macrophage cells, which interact directly with the microglia. Although the full range of mechanisms is still poorly understood, it seems that there is a very close communication between the peripheral immune system and the central nervous system, causing an initial inflammatory runaway. Thus, it seems opportune in our cohort for which neuroinflammation is suspected, to combine the quantification of the main circulating mediators (cytokine and chemokine assays) and cellular (PBMC cell sorting [Peripheral blood mononuclear cells], with transcriptomic and epigenomic analysis as well as proteomics with time-of-flight cytometry or Cytof) easily accessible in the blood of patients in order to best describe in a minimally invasive manner this inflammatory reaction and to be able propose a follow-up and a potential therapeutic strategy.

03

Conditions studied

  • Severe COVID-19

Keywords

  • SARS-Cov 2 (Severe Acute Respiratory Syndrome-Coronavirus 2)
  • Covid-19
  • Dexmedetomidine
  • Neuroinflammation
  • [18F]-DPA-714
  • PET-MRI
04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patient admitted in ICU for COVID-19 ARDS and alive 2 years after infection

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patient (age ≥ 18 years at the time of inclusion) under 75 years old
  • COVID-19 infection documented by PCR test performed on a nasopharyngeal swab or from a bronchoalveolar sample
  • High affinity homozygous TPSO genotyping for [18F] -DPA-714 or heterozygous intermediate affinity for [18F] -DPA-714
  • Patient who was hospitalized in intensive care for ARDS after COVID infection which required mechanical ventilation and deep sedation for at least 24 hours
  • Patient alive at 24 months (+ 24 months) after discharge from intensive care
  • Signature of
  • Patient affiliated to a National French social security system, excluding (French) State Medical Aid (SMA)

For the group of patients exposed to dexmedetomidine:

  • Administration of dexmedetomidine for at least 24 hours during intensive care hospitalization

For the group of patients not exposed to dexmedetomidine:

  • No administration of dexmedetomidine during intensive care hospitalization

Exclusion criteria

Exclusion Criteria:

  • Protected adult (under legal protection, guardianship or curatorship)
  • Pregnancy or breast-feeding
  • to PET or MRI examination
  • Severe renal impairment ( \<30 mL / min)
  • Contraindication to the administration of the radiopharmaceutical agent [18F]-DPA-714
  • Serious neurological history at admission to intensive care:

    • Stroke
    • Severe head trauma
    • Dementia with loss of autonomy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Observational model
Other
Time perspective
Other
Enrollment
72 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Exposed to Dexmedetomidine during ICU stay

    Dexmedetomidine has been administered in accordance with its MA (at least 24 hours continuously with a starting dose of 0.7 µg/kg/h and then adjusted to sedation scores between 0.4 and 1.1 µg/kg/h), as part of care, prior to inclusion in the protocol

  • Not Exposed to Dexmedetomidine during ICU stay

    Standard of care

06

What researchers measure

Primary outcomes

  1. Mean of SUVr of [18F]-DPA-714 in frontal lobes compared to cerebellar lobes

    Persistent neuroinflammation is measured by \[18F\]-DPA-714 signal intensity obtained on PET-MRI imaging on the 2 frontal lobes (freesurfer segmentation, with signal intensity being the ratio of the measurement in the frontal lobes to that in the cerebellar lobes. The standard fixation will be expressed as an indexed value compared to the control value. The intensity of the \[18F\]-DPA-714 signal is the SUV (standard uptake value) or quantity of radioactivity fixed in the tissue which will be measured in each region of interest (frontal lobes and cerebellar lobes = reference) and related to the quantity of radioactivity injected for the examination. This signal will be corrected by taking into account the weight, the amount of radioactivity injected for the examination and the SNPrs6971 genotype (low, medium or high affinity of the radiotracer for its ligand). The ratio of SUV in the frontal lobes to the SUV of the cerebellar lobes

    Time frame: 24 months (+ 24 months) after ICU discharge

Secondary outcomes

  1. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score GOSE

    Time frame: 24 months (+24 months) after ICU discharge

  2. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score Rankin

    Time frame: 24 months (+24 months) after ICU discharge

  3. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score: presence of memory impairment assessed by MOCA

    Time frame: 24 months (+24 months) after ICU discharge

  4. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score: presence of memory impairment assessed by GOAT score

    Time frame: 24 months (+24 months) after ICU discharge

  5. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score: presence of depressive state by HADS

    Time frame: 24 months (+24 months) after ICU discharge

  6. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score: dependencies by the Barthel score

    Time frame: 24 months (+24 months) after ICU discharge

  7. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score: presence of a PTSD

    Time frame: 24 months (+24 months) after ICU discharge

  8. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score: the quality of life scale SF36

    Time frame: 24 months (+24 months) after ICU discharge

  9. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score Qolibri

    Time frame: 24 months (+24 months) after ICU discharge

  10. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score GDS

    Time frame: 24 months (+24 months) after ICU discharge

  11. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score: detection of anorexia by the DSM-IV-TR scale and DSM-V.

    Time frame: 24 months (+24 months) after ICU discharge

  12. Neuro-cognitive lesions acquired using clinical assessment score means

    Neuro-cognitive lesions acquired using clinical assessment score: detection of anorexia by the DSM-V

    Time frame: 24 months (+24 months) after ICU discharge

  13. Mean of neuro-cognitive lesions acquired using diffusion tensor brain MRI

    Neuro-cognitive lesions acquired using diffusion tensor brain MRI will be documented by: overall brain volume, brain volume in certain regions (corpus callosum, thalami, cerebrospinal fluid, cerebellum), and an assessment of white matter lesions (measurement of the anisotropy fraction (FA), mean diffusivity (MD), L1 and Lt) and this also at the level of the overall brain and in certain regions precisely.

    Time frame: 24 months (+24 months) after ICU discharge

  14. Study the distribution of SUVr in different freesurfer regions on the PET-MRI examination

    DPA signal will be quantified in each ROIs and will be analysed.

    Time frame: 24 months (+24 months) of discharge from intensive care

07

Study locations

1 of 1 sites recruiting
  • Anesthesy department - Hôpital Pitié Salpêtrière
    Paris, 75013, France
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Data are available upon reasonable request The procedures carried out with the French data privacy authority (CNIL, Commission nationale de l'informatique et des libertés) do not provide for the transmission of the database, nor do the information and consent documents signed by the patients. Consultation by the editorial board or interested researchers of individual participant data that underlie the results reported in the article after deidentification may nevertheless be considered, subject to prior determination of the terms and conditions of such consultation and in respect for compliance with the applicable regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 3 months and ending 3 years following article publication. Requests out of these time frame can also be submitted to the sponsor

Access criteria: Researchers who provide a methodologically sound proposal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Feb 2026, 46 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 46 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Feb 10, 2022
StartActual
Mar 21, 2022
Primary completionEst.
Feb 4, 2026
CompletionEst.
Feb 4, 2026
Last update
Dec 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05233605
Responsible party
Sponsor
First posted
Feb 10, 2022
Start date
Mar 21, 2022
Primary completion
Feb 4, 2026 (estimated)
Completion
Feb 4, 2026 (estimated)
Last update
Dec 24, 2024

Study contacts

Vincent DEGOS, Pr
Contact
vincent.degos@aphp.fr
(0)1 42 16 37 61 ext. +33
Laurence JALIN, Dr
Contact
laurence.jalin@aphp.fr
(0)1 42 16 34 23 ext. +33
Vincent DEGOS, Pr
study director · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion